
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 25 years ago
Introductionover 25 years ago
Threshold Level or Not for Low-Density Lipoprotein Cholesterolover 25 years ago
Statins--Differences and Similaritiesover 25 years ago
What Do the Statin Trials Tell Us?over 25 years ago
New Therapies on the Horizonover 25 years ago
A New Statin: A New Standard





